World News Intel

The Nigerian Exchange Group Plc (NGX Group) has announced changes in its top leadership, hallmarked by the appointment of Mr. Temi Popoola as its Group Chief Executive Officer and Chief Executive Officer (GMD/CEO) designate effective 1 January 2024.

Jude Chiemeka

Popoola, currently the CEO of the Nigerian Exchange Limited (NGX), will be succeeding, Mr. Oscar N. Onyema, OON, who embarks on terminal leave from 1 January 2024.

To succeed Popoola as NGX CEO is Mr. Jude Chiemeka, the Executive Director for Capital Markets.

In announcing the leadership changes, the NGX Group said it hopes this will steer the group to unprecedented levels.

It said via its official X handle: “We are excited to share two significant leadership changes within Nigerian Exchange Group Plc (NGX Group) and Nigerian Exchange Limited (NGX). Mr. Temi Popoola, the CEO of NGX, has been appointed as the GMD/CEO designate of NGX Group, effective 1 January 2024.

Oscar Onyema

“We extend heartfelt gratitude to Mr. Onyema for his exceptional leadership & invaluable contributions, first as the CEO of The NSE from 2011 – 2021 and thereafter as the GMD/CEO of NGX Group from 2021 – 2024. Wishing him continued success in all his future endeavours.

“As we warmly welcome Mr. Temi Popoola and Mr. Jude Chiemeka to their new roles, we are confident that their wealth of experience and strategic vision will steer NGX Group and NGX to unprecedented heights.

“Mr. Onyema led the stabilization, growth, demutualization & restructuring of The NSE to NGX Group, a public company limited by shares, which is a significant milestone in the organisation’s history. He also led the listing of the Company on the Main Board of NGX.

“These changes pave the way for the retirement of our esteemed GMD/CEO, Mr. Oscar N. Onyema, OON, who embarks on terminal leave from 1 January 2024, concluding his illustrious tenure on 31 March 2024.”

Source link

Share.
Leave A Reply

Exit mobile version

Subscribe For Latest Updates

Sign up to best of business news, informed analysis and opinions on what matters to you.
Invalid email address
We promise not to spam you. You can unsubscribe at any time.
Thanks for subscribing!